Clinical Trials

PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]


Study ID
A031704

NCT Number
NCT03793166 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0629

Principle Investigator
Dr. Alter, Robert

Phase
II/III

Sponsor
Alliance for Clinical Trials In Oncology Foundation


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now